Gram-negative bacteria (GNB) are a leading cause of bloodstream infections (BSI) and management is complicated by antibiotic resistance. The Accelerate Pheno™ system (ACC) can provide rapid organism identification and antimicrobial susceptibility testing (AST).
A retrospective, pre-intervention/post-intervention study was conducted to compare management of non-critically ill patients with GNB BSI before and after implementation of a bundled initiative. This bundled initiative included dissemination of a clinical decision algorithm, ACC testing on all GNB isolated from blood cultures, real-time communication of results to the Antimicrobial Stewardship Program (ASP), and prospective audit with feedback by the ASP. The pre-intervention period was January 2018 through December 2018, and the post-intervention period was May 2019 through February 2020.
Seventy-seven and 129 patients were included in the pre-intervention and post-intervention cohorts, respectively. When compared with the pre-intervention group, the time from Gram stain to AST decreased from 46.1 to 6.9 h (p < 0.001), and the time to definitive therapy (TTDT) improved from 32.6 to 10.5 h (p < 0.001). Implementation led to shorter median total duration of antibiotic therapy (14.2 vs 9.5 days; p < 0.001) and mean hospital length of stay (7.9 vs 5.3 days; p = 0.047) without an increase in 30-day readmissions (22.1% vs 14%; p = 0.13).
Implementation of an ASP-bundled approach incorporating the ACC aimed at optimizing antibiotic therapy in the management GNB BSI in non-critically ill patients led to reduced TTDT, shorter duration of antibiotic therapy, and shorter hospital length of stay without adversely affecting readmission rates.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Anderson DJ, Moehring RW, Sloane R, et al. Bloodstream infections in community hospitals in the 21st century: a multicenter cohort study. PLoS ONE. 2014;9:e91713.
Carrara E, Pfeffer I, Zusman O, Leibovici L, Paul M. Determinants of inappropriate empirical antibiotic treatment: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:548–53.
Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742–8.
Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2010;54:5099–104.
Battle SE, Bookstaver PB, Justo JA, et al. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis. J Antimicrob Chemother. 2017;72:299–304.
Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:15–23.
Henig O, Kay KS, Chandramohan S, et al. The hypothetical impact of Accelerate Pheno (ACC) on time to effective therapy and time to definitive therapy for bloodstream infections due to drug-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2019;74:i32–9.
Humphries R, DiMartino T. Effective implementation of the Accelerate Pheno system for positive blood cultures. J Antimicrob Chemother. 2019;74:i40–3.
Özenci V, Rossolini GM. Rapid microbial identification and antimicrobial susceptibility testing to drive better patient care: an evolving scenario. J Antimicrob Chemother. 2019;74:i2–5.
Wenzler E, Timbrook TT, Wong JR, Hurst JM, MacVane SH. Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections. Am J Health-Syst Pharm. 2018;75:1191–202.
Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis. 2014;59:s134-145.
Erickson RM, Tritle BJ, Spivak ES, Timbrook TT. Impact of an antimicrobial stewardship bundle for uncomplicated gram-negative bacteremia. Open Forum Infect Dis. 2019;6:ofz490.
Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009;31:146–50.
Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistance infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:155–64.
Institute of Medicine Committee on Emerging Microbial Threats to Health in the 21st C. In: Smolinski MS, Hamburg MA, Lederberg J, eds. Microbial Threats to Health: Emergence, Detection, and Response. Washington (DC): National Academies Press (US) Copyright 2003 by the National Academy of Sciences. All rights reserved; 2003.
Antibiotic/antimicrobial resistance. US Department of Health and Human Services Centers for Disease Control and Prevention website. http://www.cdc.gov/drugresistance/. Accessed 18 Feb 2016.
Infectious Diseases Society of America. Bad bug, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Infectious Diseases Society of America website. http://www.idsociety.org/BBND/. Accessed 18 Feb 2016.
Teshome B, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of exposure to antipseudomonal beta-lactam antibiotics in the critically ill and development of new resistance. Pharmacotherapy. 2019;39:261–8.
Seddon MM, Bookstaver PB, Justo JA, et al. Role of early de-escalation of antimicrobial therapy on risk of Clostridioides difficile infection following Enterobacteriaceae bloodstream infections. Clin Infect Dis. 2019;69:414–20.
Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014;59:S97–100.
Barlam TF, Cosgrove SE, Abbo LM, et al. Executive summary: implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:1197–202.
Hill B, Narayannan N, Palavecino E, et al. The role of an antimicrobial stewardship team in the use of rapid diagnostic testing in acute care’ an official position statement of the Society of Infectious Diseases Pharmacists. Infect Control Hosp Epidemiol. 2018;39:473–5.
Banerjee R, Komarow L, Virk A, et al. Randomized trial evaluating clinical impact of RAPid IDdentification and susceptibility testing for gram negative bacteremia (RAPIDS-GN). Clin Infect Dis 2020 (in press)
Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69:1091–8.
Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis. 2018;66:172–7.
Harvey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011;15:R267.
Fong K, Dubrovskaya K, Siegfried J, et al. Streamlining to oral beta-lactam vs fluoroquinolone as definitive therapy for Enterobacteriaceae bacteremia. Open Forum Infect Dis. 2018;5:S321.
Gumbleton R, Ott J, Townsend M, et al. Treatment failure rates in patients receiving low versus high oral bioavailability antibiotics for gram-negative bacteremia. J Am Coll Clin Pharm. 2018;1:220.
Kutob LF, Justo JA, Bookstaver PB, et al. Effectiveness of oral antibiotics for definitive therapy of gram-negative bloodstream infections. Int J Antimicrob Agents. 2016;48:498–503.
The authors wish to thank the microbiology technicians at the Allegheny Health Network microbiology laboratory for their support and dedication in the utilization and optimization of the Accelerate PhenoTM System
Conflict of interest
TLW has received consulting fees from Accelerate Diagnostics. DC has received speaking honoraria from Merck. All the other authors report no conflict of interest relating to the current study.
About this article
Cite this article
Walsh, T.L., Bremmer, D.N., Moffa, M.A. et al. Impact of an Antimicrobial Stewardship Program-bundled initiative utilizing Accelerate Pheno™ system in the management of patients with aerobic Gram-negative bacilli bacteremia. Infection (2021). https://doi.org/10.1007/s15010-021-01581-1
- Rapid diagnostic testing
- Accelerate Pheno™
- Gram-negative bacteremia
- Bloodstream infection
- Antimicrobial stewardship